Invention Grant
- Patent Title: Dendritic cell composition
-
Application No.: US16065037Application Date: 2016-12-22
-
Publication No.: US10882891B2Publication Date: 2021-01-05
- Inventor: Slavoljub Milosevic , Christian Ellinger , Carina Wehner , Dolores Schendel
- Applicant: MEDIGENE IMMUNOTHERAPIES GMBH , HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
- Applicant Address: DE Planegg-Martinsried; DE Neuherberg
- Assignee: MEDIGENE IMMUNOTHERAPIES GMBH,HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
- Current Assignee: MEDIGENE IMMUNOTHERAPIES GMBH,HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)
- Current Assignee Address: DE Planegg-Martinsried; DE Neuherberg
- Agency: Clark & Elbing LLP
- Priority: EP15202329 20151223,EP16190399 20160923
- International Application: PCT/EP2016/082445 WO 20161222
- International Announcement: WO2017/109110 WO 20170629
- Main IPC: C07K14/47
- IPC: C07K14/47 ; C12N5/0784 ; A61K38/00 ; C12N5/0783 ; A61K39/00 ; A61P35/00 ; A61K35/17

Abstract:
The present invention contemplates dendritic cell compositions. The dentritic cell compositions employ MHC class-II targeting signals fused to an antigen or fragment thereof to obtain MHC II presentation of the antigen or fragment thereof. In particular, the invention refers to a dendritic cell vaccine comprising dendritic cells expressing a MHC class-II targeting signal fused to an antigen or fragment thereof. Dendritic cell vaccines for the stimulation of an immune response against melanoma-associated antigen are also described.
Public/Granted literature
- US20190000949A1 DENDRITIC CELL COMPOSITION Public/Granted day:2019-01-03
Information query